Phase I Study of Anti–Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer

2001473 citationsJournal Article

Authors

Francisco Robert · Birmingham VA Medical Center

Mark P. Ezekiel · Birmingham VA Medical Center

Sharon A. Spencer · Birmingham VA Medical Center

Ruby F. Meredith · Birmingham VA Medical Center

James A. Bonner · Birmingham VA Medical Center

M.B. Khazaeli · Birmingham VA Medical Center

Mansoor N. Saleh

Abstract

Cetuximab can be safely administered with RT. The recommended dose for phase II/III studies is a loading dose of 400 to 500 mg/m(2) and a maintenance weekly dose of 250 mg/m(2).

Topics & Keywords

Head and Neck Cancer Studies Lung Cancer Treatments and Mutations Brain Metastases and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 19, Issue 13, pp. 3234-3243

DOI: 10.1200/jco.2001.19.13.3234

Field-Weighted Citation Impact: 37.61